Expression of p53 in imprint smears of endometrial carcinoma

Diagnostic Cytopathology

Volumn 42, Issue 5, 2014, Pages 416-422

  Konstantinos, Kosmas ^a   Marios, Stamoulas ^a   Anna, Marouga ^b   Nikolaos, Kavantzas ^b   Efstratios, Patsouris ^b   Paulina, Athanassiadou ^b  

^a Anti cancer Oncological Hospital St Savvas   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

endometrial carcinoma; imprint cytology; p53

Indexed keywords

PROTEIN P53;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CYTOLOGY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; CARCINOMA, ENDOMETRIOID; CYTODIAGNOSIS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; GENE EXPRESSION; GENETICS; HYSTERECTOMY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURGERY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYTODIAGNOSIS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899455284     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.23056     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
3. Prat J,. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004; 35: 649-662.
4. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Muñoz J, Argüelles R, Machin P, Prat J,. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32: 569-577.
5. Horn LC, Meinel A, Handzel R, Einenkel J,. Histopathology of endometrial hyperplasia and endometrial carcinoma: An update. Ann Diagn Pathol 2007; 11: 297-311.
6. Kurman RJ, (ed). Blaustein's Pathology of the Female Genital Tract, 5th ed. New York: Springer; 2002. pp 501-560.
7. Pansare V, Munkarah AR, Schimp V, et al. Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Mod Pathol 2007; 20: 35-43.
8. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ, Oren M,. Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study. Proc Natl Acad Sci USA 2000; 97: 11250-11255.
9. Albitar L, Carter MB, Davies S, Leslie KK,. Consequences of the loss of p53, RB1, and PTEN: Relationship to gefitinib resistance in endometrial cancer. Gynecol Oncol 2007; 106: 94-104.
10. Hsu SM, Raine L, Fanger H,. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 1981; 75: 816-821.
11. Mariani A, Sebo TJ, Webb MJ, et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev 2003; 27: 434-441.
12. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L,. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic pathways. Cancer 2000; 88: 814-824.
13. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW,. Immunohistochemical profile of endometrial adenocarcinoma: A study of 61 cases and review of the literature. Mod Pathol 2000; 13: 379-388.
14. Norimatsu Y, Miyamoto M, Kobayashi TK, et al. Diagnostic utility of phosphatase and tensin homolog, beta-catenin, and p53 for endometrial carcinoma by thin-layer endometrial preparations. Cancer 2008; 114: 155-164.
15. Norimatsu Y, Ohsaki H, Yanoh K, Kawanishi N, Kobayashi TK,. Expression of immunoreactivity of nuclear findings by p53 and cyclin a in endometrial cytology: Comparison with endometrial glandular and stromal breakdown and endometrioid adenocarcinoma grade 1. Diagn Cytopathol 2011. doi: 10.1002/dc.21837.
16. Shih HC, Shiozawa T, Kato K, et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: Positive staining for cyclin A as a poor prognostic indicator. Hum Pathol 2003; 34: 471-478.
17. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W,. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol 1999; 74: 468-471.
18. Hamel NW, Sebo TJ, Wilson TO, et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 1996; 62: 192-198.
19. Appel ML, Edelweiss MI, Fleck J, et al. P53 and BCL-2 as prognostic markers in endometrial carcinoma. Pathol Oncol Res 2008; 14: 23-30.
20. Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ,. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 1996; 74: 562-567.
21. Simionescu C, Georgescu CV, Mǎrgǎritescu C, et al. P53 and PCNA immunoexpression in endometrial carcinomas. Rom J Morphol Embryol 2006; 47: 137-141.
22. Watanabe J, Nishimura Y, Tsunoda S, Kawaguchi M, Okayasu I, Kuramoto H,. Liquid-based preparation for endometrial cytology - usefulness for predicting the prognosis of endometrial carcinoma preoperatively. Cancer 2009; 117: 254-263.
23. Inaba F, Kawamata H, Teramoto T, Fukasawa I, Inaba N, Fujimori T,. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol Rep 2005; 13: 17-24.
24. Garg K, Leitao MM Jr, Wynveen CA, et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol 2010; 23: 80-92.
25. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB,. Interpretation of p53 immunoreactivity in endometrial carcinoma: Establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004; 23: 129-137.
26. Lachance JA, Darus CJ, Rice LW,. Surgical management and postoperative treatment of endometrial carcinoma. Rev Obstet Gynecol 2008; 1: 97-105.
27. Athanassiadou P, Athanassiades P, Grapsa D, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: A prospective immunocytochemical study. Int J Gynecol Cancer 2007; 17: 697-704.
28. Fayallah EA, Hemida RA, Gamal AM, et al. Pretreatment study of P53 overexpression for selection of candidates for pelvic lymphadenectomy in clinical stage I endometrial carcinoma: A randomized-controlled study. Arch Gynecol Obstet 2011; 283: 617-622.
29. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA,. Immunophenotypic diversity of endometrial adenocarcinomas: Implications for differential diagnosis. Mod Pathol 2006; 19: 1091-1100.
30. O'Neill CJ, McCluggage WG,. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006; 13: 8-15.
31. Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG,. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 2007; 26: 328-333.
32. Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W,. MIB-1 in endometrial carcinoma: Prognostic significance with 5-year follow-up. Gynecol Oncol 1999; 75: 432-436.
33. Salvesen HB, Iversen OE, Akslen LA,. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 1998; 4: 2779-2785.
34. Al Kushi A, Lim P, Aquino-Parsons C, Gilks CB,. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 2002; 15: 365-371.
35. Alkushi A, Clarke BA, Akbari M, et al. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007; 20: 1156-1165.
36. Salvesen HB, Stefansson I, Kalvenes MB, Das S, Akslen LA,. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 2002; 94: 2185-2191.
37. Salvesen HB, Stefansson I, Kretzschmar EI, et al. Significance of PTEN alterations in endometrial carcinoma: A population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol 2004; 25: 1615-1623.
38. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924-930.
39. Mutter GL,. PTEN, a protean tumor suppressor. Am J Pathol 2001; 158: 1895-1898.
40. Pallares J, Bussaglia E, Martínez-Guitarte JL, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: A tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005; 18: 719-727.
41. Weintraub J, Morabia A,. Efficacy of a liquid-based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer. Diagn Cytopathol 2000; 22: 52-59.
42. Michael CW, Hunter B,. Interpretation of fine-needle aspirates processed by the ThinPrep technique: Cytologic artifacts and diagnostic pitfalls. Diagn Cytopathol 2000; 23: 6-13.
43. Norimatsu Y, Kouda H, Kobayashi TK, et al. Utility of thin-layer preparations in the endometrial cytology: Evaluation of benign endometrial lesions. Ann Diagn Pathol 2008; 12: 103-111.
44. Patel C, Ullal A, Roberts M, et al. Endometrial carcinoma detected with SurePath liquid-based cervical cytology: Comparison with conventional cytology. Cytopathology 2009; 20: 380-387.
45. Buccoliero AM, Gheri CF, Castiglione F, et al. Liquid-based endometrial cytology: Cyto-histological correlation in a population of 917 women. Cytopathology 2007; 18: 241-249.
46. Norimatsu Y, Kouda H, Kobayashi TK, et al. Utility of liquid-based cytology in endometrial pathology: Diagnosis of endometrial carcinoma. Cytopathology 2009; 20: 395-402.